Conferences - Results from #460

SUO 2024: Novel Approaches to Radiotherapy to Reduce Patient Burden December 6, 2024

SUO 2024: Sexual Satisfaction Despite Sexual Dysfunction December 6, 2024

SUO 2024: Efficacy and Safety of Padeliporfin VTP for Treatment of Low-Grade UTUC: ENLIGHTED Phase 3 study December 6, 2024

SUO 2024: Clinical Progression of Prostate Cancer from Active Surveillance is Predicted by Decipher® Genomic Classifier Score on Index Biopsy Independent from Risk Assessment by MRI Characteristics December 6, 2024

SUO 2024: CORE-008: A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk NMIBC December 6, 2024

SUO 2024: Genitourinary Cancer Care among Geriatric Patients December 6, 2024

SUO 2024: Access to Care for Resource Challenged Populations: Tele-Cystoscopy December 6, 2024

SUO 2024: The Cretostimogene Grenadenorepvec Expanded Access Program in Patients with NMIBC Unresponsive to BCG December 6, 2024

SUO 2024: Multicenter Experience with First-Line Intravesical Gemcitabine-Docetaxel Versus Bacillus Calmette-Guerin for High-Risk NMIBC December 6, 2024

SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting December 6, 2024

SUO 2024: AI in Prostate Cancer: Diagnostic Hype and Hope December 6, 2024

SUO 2024: Incidence and Pathologic Outcomes of Cystectomy in Patients with BCG-Unresponsive NMIBC with CIS Following Treatment with Nadofaragene Firadenovec December 6, 2024

SUO 2024: An Artificial Intelligence Powered Model to Predict Response to Intravesical BCG Versus Gemcitabine-Docetaxel for High Risk NMIBC December 6, 2024

SUO 2024: Co-formulated Vibostolimab/pembrolizumab or Co-formulated Favezelimab/pembrolizumab for Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle Invasive Bladder Cancer: Cohort C of Phase II KEYNOTE-057 Trial December 6, 2024

SUO 2024: A Phase I Dose-Escalation Study of UGN-301 (Zalifrelimab) as Monotherapy and in Combination with Other Agents in Patients with Recurrent Non-muscle Invasive Bladder Cancer December 6, 2024

SUO 2024: ADVANCED-2: Phase 2 Open-Label Study to Evaluate Safety and Anti-Tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-Grade Non-Muscle Invasive Bladder Cancer December 6, 2024

SUO 2024: Prostate Cancer Screening with Biomarkers and MRI–A European Perspective December 6, 2024

SUO 2024: The Impact of BCG Shortage on Disease Recurrence for Patients with Non-Muscle Invasive Bladder Cancer: A SEER Patterns of Care Analysis. December 6, 2024

SUO 2024: Voided Urine Cell-Free DNA as a Biomarker for Upper Tract Urothelial Carcinoma December 6, 2024

SUO 2024: Measuring and Mitigating Decision Regret in the Management of Genitourinary Cancers: Honing our Shared Decision-Making Skills December 6, 2024

Page 24 of 616